Chronic obstructive pulmonary disease

Indian Journal of Medical Research

Volumn 137, Issue 2, 2013, Pages 251-269

  Vijayan, V K ^a,b  

^a UNIVERSITY OF DELHI   (India)

^b BHOPAL MEMORIAL HOSPITAL AND RESEARCH CENTRE   (India)

Author keywords

Air pollution; Airflow limitation; Bronchodilators; Chronic obstructive pulmonary disease; Exacerbations; Lung; Pulmonary rehabilitation; Smoking

Indexed keywords

AMINOPHYLLINE; ANTIBIOTIC AGENT; AZITHROMYCIN; BRONCHODILATING AGENT; CORTICOSTEROID; FORMOTEROL FUMARATE; GLYCOPYRRONIUM BROMIDE; INDACATEROL; IPRATROPIUM BROMIDE; MATRIX METALLOPROTEINASE; PHOSPHODIESTERASE IV INHIBITOR; PREDNISOLONE; PROTEINASE; PROTEINASE INHIBITOR; ROFLUMILAST; SALBUTAMOL; SALMETEROL; SALMETEROL XINAFOATE; THEOPHYLLINE; TIOTROPIUM BROMIDE;

AIR POLLUTION; AIRWAY OBSTRUCTION; APOPTOSIS; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; DEATH; DIARRHEA; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; ENDOTHELIAL MICROPARTICLE; ENVIRONMENTAL FACTOR; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEADACHE; HEREDITY; HOSPITAL ADMISSION; HUMAN; IMMUNOLOGY; INFLAMMATION; LOW DRUG DOSE; LUNG RESECTION; LUNG VOLUME; NAUSEA; NUTRITIONAL SUPPORT; OXYGEN THERAPY; PATHOLOGY; PULMONARY REHABILITATION; REVIEW; RISK FACTOR; SIDE EFFECT; SLEEP DISORDER; SMOKING; WEIGHT REDUCTION;

AIR POLLUTION; ASTHMA; BRONCHODILATOR AGENTS; COMORBIDITY; HUMANS; INDIA; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS;

EID: 84875516883     PISSN: 09715916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (180)

1. [No authors listed]. Definition and classification of chronic bronchitis for clinical and epidemiological purposes. A report to the Medical Research Council by their Committee on the Aetiology of Chronic Bronchitis. Lancet 1965; 1: 775-9.
2. American Thoracic Society. Definitions and classification of chronic bronchitis, asthma and pulmonary emphysema. Am Rev Respir Dis 1962; 85: 762-7.
3. Snider GL, Kleinerman J, Thurlbeck WM, Bengali ZH. The definition of emphysema: report of a National Heart, Lung and Blood Institute, Division of \lunlg Diseases, workshop. Am Rev Respir Dis 1985; 132: 182-5.
4. Reid L. The pathology of emphysema. Chicago: Year Book Medical Publishers; 1967.
5. McDonough JE, Yuan R, Suzuki M, Seyednejad N, Elliott WM, Sanchez PG, et al. Small-airway obstruction and emphysema in chronic obstructive pulmonary disease. N Engl J Med 2011; 365: 1567-75.
6. Mitzer W. Emphysema - a disease of small airways or lung parenchyma? N Engl J Med 2011; 365: 1637-9.
7. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of Chronic Obstructive Pulmonary Disease (Revised 2011). Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2011_Feb21_pdf, accessed on September 16, 2012.
8. Osler W. The principles and practice of medicine. New York: D. Appleton and Co.; 1892.
9. Lindberg A, Jonsson AC, Ronmark E, Lundgren R, Larsson LG, Lundback B. Prevalence of chronic obstructive pulmonary disease according to BTS, ERS, GOLD and ATS criteria in relation to doctor's diagnosis, symptoms, age, gender and smoking habits. Respiration 2005; 72: 471-9.
10. Cerveri I, Accordini S, Verlato G, Corsico A, Zoia MC, Casali L, et al. European Community Respiratory Health Survey (ECRHS) Study Group. Variations in the prevalence across countries of chronic bronchitis and smoking habits in young adults. Eur Respir J 2001; 18: 85-92.
11. Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global burden of COPD: systematic review and meta-analysis. Eur Respir J 2006; 28: 523-32.
12. Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, et al. BOLD Collaborative Research Group. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007; 370: 741-50.
13. Menezes AM, Perez-Padilla R, Hallal PC, Jardim JR, Muiño A, Lopez MV, et al, PLATINO Team. Worldwide burden of COPD in high-and low-income countries. Part II. Burden of chronic obstructive lung disease in Latin America: the PLATINO study. Int J Tuberc Lung Dis 2008; 12: 709-12.
14. Fang X, Wang X, Bai C. COPD in China: the burden and importance of proper management. Chest 2011; 139: 920-9.
15. Wig KL, Guleria JS, Bhasin RC, Holmes E Jr, Vasudeva YL. Singh H. Certain clinical and epidemiological patterns of chronic obstructive lung disease as seen in Northern India. Indian J Chest Dis 1964; 6: 183-94.
16. Viswanathan R. Epidemiology of chronic bronchitis: morbidity survey in Patna urban area. Indian J Med Res 1966; 54: 105-11.
17. Radha TG, Gupta CK, Singh A, Mathur N. Chronic bronchitis in an urban locality of New Delhi - an epidemiological survey. Indian J Med Res 1977; 66: 273-85.
18. Jindal SK. A field study on follow up at 10 years of prevalence of chronic obstructive pulmonary disease & peak expiratory flow rate. Indian J Med Res 1993; 98: 20-6.
19. Thiruvengadam KV, Raghava TP, Bhardwaj KV. Survey of prevalence of chronic bronchitis in Madras city. In: Viswanathan R, Jaggi OP, editors. Advances in chronic obstructive lung disease. Delhi: Asthma and Bronchitis Foundation of India; 1977. p. 59-6.
20. Ray D, Abel R, Selvaraj KG. A 5-yr prospective epidemiol-ogical studyof chronic obstructive pulmonary disease in rural South India. Indian J Med Res 1995; 101: 238-44.
21. Jindal SK, Aggarwal AN, Gupta D, Agarval R, Kumar R, Kaur T, et al. Indian study on epidemiology of asthma, respiratory symptoms and chronic bronchitis in adults (INSEARCH). Int J Tuberc Lung Dis 2012; 16: 1270-7.
22. Gooptu B, Ekeowa UI, Lomas DA. Mechanisms of emphysema in α1-antitrypsin deficiency: molecular and cellular insights. Eur Respir J 2009; 34: 475-88.
23. Stoller JK, Aboussouan LS. A review of α1-antitrypsin deficiency. Am J Respir Crit Care Med 2012; 185: 246-59.
24. Pillai SG, Ge D, Zhu G, Kong X, Shianna KV, Need A, et al; ICGN Investigators. A genome-wide association study in chronic obstructive pulmonary disease (COPD): identification of two major susceptibility loci. PLoS Genet 2009; 5: e000421.
25. Cho MH, Boutaoui N, Klanderman BJ, Sylvia JS, Ziniti JP, Hersh C, et al. Variants in FAM13A are associated with chronic obstructive pulmonary disease. Nat Genet 2010; 42: 200-2.
26. Bosse Y. Updates on the COPD gene list. Int J Chron Obstruct Pulmon Dis 2012; 7: 607-31.
27. Cho MH, Castaldi PJ, Wan ES, Siedlinski M, Hersh CP, Demeo D, et al; ICGN Investigators; ELLIPSE \investigators; COPD Gene investigaors. A genome-wide association study of COPD identifies a susceptibility locus on chromosome 19q13. Hum Mol Genet 2012; 21: 947-5.
28. Repapi E, Sayers I, Wain LV, Burton PR, Johnson T, Obeidat M, et al. Genome-wide association study identifies five loci associated with lung function. Nat Genet 2010; 42: 36-44.
29. Hancock DB, Eijgelsheim M, Wilk JB, Gharib SA, Loehr LR, Marciante KD, et al. Meta-analyses of genome-wide association studies identify multiple loci associated with pulmonary function. Nat Genet 2010; 42: 45-52.
30. Imboden M, Bouzigon E, Curjuric I, Ramasamy A, Kumar A, Hancock DB, et al. Genome-wide association study of lung function decline in adults with and without asthma. J Allergy Clin Immunol 2012; 129: 1218-28.
31. Forey BA, Thornton AJ, Lee PN. Systematic review with meta-analysis of the epidemiological evidence relating smoking to COPD, chronic bronchitis and emphysema. BMC Pulm Med 2011; 11: 36.
32. Eisner MD, Anthonisen N, Coultas D, Kuenzli N, Perez-Padilla R, Postma D, et al. An official American Thoracic Society public policy statement: novel risk factors and the global burden of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010; 182: 693-718.
33. Lindberg A, Eriksson B, Larsson LG, Rönmark E, Sandström T, Lundbäck B, et al. Seven-year cumulative incidence of COPD in an age-stratified general population sample. Chest 2006; 129: 879-85.
34. Lokke A, Lange P, Scharling H, Fabricius P, Vestbo J. Developing COPD: a 25 year follow up study of the general population. Thorax 2006; 61: 935-9.
35. Jindal SK, Aggarwal AN, Chaudhry K, Chhabra SK, D'Souza GA, Gupta D, et al. Asthma Epidemiology Study Group. A multicentric study on epidemiology of chronic obstructive pulmonary disease and its relationship with tobacco smoking and environmental tobacco smoke exposure. Indian J Chest Dis Allied Sci 2006; 48: 23-9.
36. Ko FW, Hui DS. Air pollution and chronic obstructive pulmonary disease. Respirology 2012; 17: 395-401.
37. Kan H, Heiss G, Rose KM, Whitsel E, Lurmann F, London SJ, et al. Traffic exposure and lung function in adults: the Atherosclerosis Risk in Communities study. Thorax 2007; 62: 873-9.
38. Andersen ZJ, Hvidberg M, Jensen SS, Ketzel M, Loft S, Sørensen M, et al. Chronic obstructive pulmonary disease and long-term exposure to traffic-related air pollution: a cohort study. Am J Respir Crit Care Med 2011; 183: 455-61.
39. Yin P, Jiang CQ, Cheng KK, Lam TH, Lam KH, Miller MR, et al. Passive smoking exposure and risk of COPD among adults in China: the Guangzhou Biobank Cohort Study. Lancet 2007; 370: 751-7.
40. Eisner MD, Balmes J, Katz PP, Trupin L, yelin EH, Blanc PD, et al. Lifetime environmental tobacco smoke exposure and the risk of chronic obstructive pulmonary disease. Environ Health 2005; 4: 7.
41. Po JY, FitzGerald JM, Carlsten C. Respiratory disease associated with solid biomass fuel exposure in rural women and children: systematic review and meta-analysis. Thorax 2011; 66: 232-9.
42. Salvi SS, Barnes PJ. Chronic obstructive pulmonary disease in non-smokers. Lancet 2009; 374: 733-43.
43. World Resources Institute (WRI), UNDP, World Bank. 2007-08. World Resources: A guide to the global environment. Oxford: Oxford University Press; 2008.
44. Hu G, Zhou Y, Tian J, Yao W, Li J, Li B, et al. Risk of COPD from exposure to biomass smoke. Chest 2010; 138: 20-31.
45. Decramer M, Janssens W, Miravitlles M. Chronic obstructive pulmonary disease. Lancet 2012; 379: 1341-51.
46. Shapiro SD, Ingenito EP. The pathogenesis of chronic obstructive pulmonary disease: advances in the past 100 years. Am J Respir Cell Mol Biol 2005; 32: 367-72.
47. Macklem PT, Mead J. Resistance of central and peripheral airways measured by a retrograde catheter. J Appl Physiol 1967; 22: 395-401.
48. Hogg JC, Macklem PT, Thurlbeck WM. Site and nature of airway obstruction in chronic obstructive lung disease. N Engl J Med 1968; 278: 1355-60.
49. Laurell CB, Eriksson S. The electrophoretic alpha 1-globulin pattern of serum in alpha 1-antitrypsin deficiency. Scand J Clin Lab Invest 1963; 15: 132-40.
50. Houghton AM. Endogenous modifiers of cigarette smoke exposure within the lung. Proc Am Thorac Soc 2012; 9: 66-8.
51. Sharafkhaneh A, Hanania NA, Kim V. Pathogenesis of emphysema: from the bench to the bedside. Proc Am Thorac Soc 2008; 5: 475-7.
52. Saetta M, Turato G, Maestrelli P, Mapp CE, Fabbri LM. Cellular and structural bases of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163: 1304-9.
53. Atkinson JJ, Senior RM. Matrix metalloproteinase-9 in lung remodelling. Am J Respir Cell Mol Biol 2003; 28: 12-24.Hunninghake GW, Davidson JM, Rennard S, Szapiel S,
54. Gadek JE, Crystal RG. Elastin fragments attract macrophage precursors to diseased sites in pulmonary emphysema. Science 1981; 212: 925-7.
55. Hunnighake GM, Cho MH, Tesfaigzi Y, Soto-Quiros ME, Avila L, Lasky-Su J, et al. MMP12, lung function, and COPD in high-risk populations. N Engl J Med 2009; 361: 2599-608.
56. Shapiro SD. Proteolysis in the lung. Eur Respir J 2003; 44 (Suppl): 30s-2.
57. Agusti A, Barnes PJ. Update in chronic obstructive pulmonary disease 2011. Am J Respir Crit Care Med 2012; 185: 1171-6.
58. Pesci A, Balbi B, Majori M, Cacciani G, Bertacco S, Alciato P, et al. Inflammatory cells and mediators in bronchial lavage of patients with chronic obstructive pulmonary disease. Eur Respir J 1998; 12: 380-6.
59. Braber S, Thio M, Blokhuis BR, Henricks PA, Koelink PJ, Groot Kormelink T, et al. An association between neutrophils and immunoglobulin free light chains in the pathogenesis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 185: 817-24.
60. Chauhan S, Gupta MK, Goyal A, Dasgupta DJ. Alterations in immunoglobulin & complement levels in chronic obstructive pulmonary disease. Indian J Med Res 1990; 92: 241-5.
61. Singh B, Arora S, Khanna V. Association of severity of COPD with IgE and interleukin-1 beta. Monaldi Arch Chest Dis 2010; 73: 86-7.
62. Tkac J, Man SF, Sin DD. Systemic consequences of COPD. Ther Adv Respir Dis 2007; 1: 47-59.
63. Agusti A, Faner R. Systemic inflammation and comorbidities in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2012; 9: 43-6.
64. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J 2009; 33: 1165-85.
65. Thomsen M, Dahl M, Lange P, Vestbo J, Nordestgaard BG. Inflammatory biomarkers and co-morbidities in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 186: 982-8.
66. Mouded M, Egea EE, Brown MJ, Hanlon SM, Houghton AM, Tsai LW, et al. Epithelial cell apoptosis causes acute lung injury masquerading as emphysema. Am J Respir Cell Mol Biol 2009; 41: 407-14.
67. Aoshiba K, Yokohori N, Nagai A. Alveolar wall apoptosis causes lung destruction and emphysematous changes. Am J Respir Cell Mol Biol 2003; 28: 555-62.
68. Demedts IK, Demoor T, Bracke KR, Joos GF, Brusselle GG. Role of apoptosis in the pathogenesis of COPD and pulmonary emphysema. Respir Res 2006; 7: 53.
69. Massaro GD, Massaro D. Retinoic acid treatment abrogates elastase-induced pulmonary emphysema in rats. Nat Med 1997; 3: 675-7.
70. Gordon C, Gudi K, Krause A, Sackrowitz R, Harvey BG, Strulovici-Barel y, et al. Circulating endothelial microparticles as a measure of early lung destruction in cigarette smokers. Am J Respir Crit Care Med 2011; 184: 224-32.
71. Fletcher C, Peto R. The natural history of chronic airflow obstruction. BMJ 1977; 1: 1645-8.
72. Han MK, Wise R, Mumford J, Sciurba F, Criner GJ, Curtis JL, et al; NETT Researc Group. Prevalence and clinical correlates of bronchoreversibility in severe emphysema. Eur Respir J 2009; 35: 1048-56.
73. Calverley PM, Burge PS, Spencer S, Anderson JA, Jones PW. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax 2003; 58: 659-64.
74. Tashkin DP, Altose MD, Bleecker ER, Connett JE, Kanner RE, Lee WW, et al. The Lung Health Study: airway responsiveness to inhaled methacholine in smokers with mild to moderate airflow limitation. Am Rev Respir Dis 1992; 145: 301-10.
75. Vestbo J, Edwards LD, Scanlon PD, Yates JC, Agusti A, Bakke P, et al; ECLIPSE Investigators. Changes in Forced Expiratory Volume in 1 Second over Time in COPD. N Engl J Med 2011; 365: 1184-92.
76. MacNee W. State of the art: pathophysiology of cor pulmonale in chronic obstructive pulmonary disease. Part two. Am J Respir Crit Care Med 1994; 150: 1158-68.
77. Wells JM, Washko GR, Han MK, Abbas N, Nath H, Mamary AJ, et al for the COPD Gene Investigators; ECLIPSE Study Investigators. Pulmonary arterial enlargement and acute exacerbations of COPD. N Engl J Med 2012; 367: 913-21.
78. Agusti A, Caverley PM, Celli B, Coxson HO, Edwards LD, Lomas DA, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res 2010; 11: 122-36.
79. Boschetto P, Beghe B, Fabbri LM, Ceconi C. Link between chronic obstructive pulmonary disease and coronary artery disease: implication for clinical practice. Respirology 2012; 17: 422-31.
80. Sin DD, Wu L, Man SF. The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. Chest 2005; 127: 1952-9.
81. Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 1994; 272: 1497-505.
82. Curkendall SM, DeLuise C, Jones JK, Lanes S, Stang MR, Goehring E Jr, et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol 2006; 16: 63-70.
83. Hozawa A, Billings JL, Shahar E, Ohira T, Rosamond WD, Folsom AR, et al. Lung function and ischemic stroke incidence: the Atherosclerosis Risk in Communities study. Chest 2006; 130: 1642-9.
84. Feary JR, Rodrigues LC, Smith CJ, Hubbard RB, Gibson JE. Prevalence of major co-morbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care. Thorax 2010; 65: 956-62.
85. Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 2008; 32: 962-9.
86. de Lucas-Ramos P, Izquierdo-Alonso JL, Moro JMR, Frances JF, Lozano PV, Bellón-Cano JM, CONSISTE study group. Chronic obstructive pulmonary disease as a cardiovascular risk factor: Results of a case-control study (CONSISTE study). Int J Chron Obstruct Pulmon Dis 2012; 7: 679-86.
87. Creutzberg EC, Schols AM, Bothmer-Quaedvlieg FC, Wouters EF. Prevalence of an elevated resting energy expenditure in patients with chronic obstructive pulmonary disease in relation to body composition and lung function. Eur J Clin Nutr 1998; 52: 396-401.
88. Laghi F. Low testosterone in chronic obstructive pulmonary disease: does it really matter? Am J Respir Crit Care Med 2005; 172: 1069-70.
89. Van Vliet M, Spruit MA, Verleden G, Kasran A, Van Herck E, Pitta F, et al. Hypogonadism, quadriceps weakness, and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 172: 1105-11.
90. Schols AM, Slangen J, Volovics L, Wouters EF. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 1791-7.
91. Schols AM. Nutrition in chronic obstructive pulmonary disease. Curr Opin Pulm Med 2000; 6: 110-5.
92. Sin DD, Jones RL, Mannino DM, Paul Man SF. Forced expiratory volume in 1 second and physical activity in the general population. Am J Med 2004; 117: 270-3.
93. Mador MJ, Bozkanat E. Skeletal muscle dysfunction in chronic obstructive pulmonary disease. Respir Res 2001; 2: 216-24.
94. Gosker HR, van Mameren H, van Dijk PJ, Engelen MP, van der Vusse GJ, Wouters EF et al. Skeletal muscle fibre-type shifting and metabolic profile in patients with chronic obstructive pulmonary disease. Eur Respir J 2002; 19: 617-25.
95. Agustí AG, Sauleda J, Miralles C, Gomez C, Togores B, Sala E, et al. Skeletal muscle apoptosis and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166: 485-9.
96. Casaburi R. Skeletal muscle function in COPD. Chest 2000; 117 (5 Suppl 1): 267S-71S.
97. Bon J, Fuhrman CR, Weissfeld JL, Duncan SR, Branch RA, Chang CC, et al. Radiographic emphysema predicts low bone mineral density in a tobacco-exposed cohort. Am J Respir Crit Care Med 2011; 183: 885-90.
98. Sin DD, Man JP, Man SF. The risk of osteoporosis in Caucasian men and women with obstructive airways disease. Am J Med 2003; 114: 10-4.
99. Biskobing DM. COPD and osteoporosis. Chest 2002; 121: 609-20.
100. de Vries F, van Staa TP, Bracke MS, Cooper C, Leufkens HG, Lammers JW. Severity of obstructive airway disease and risk of osteoporotic fracture. Eur Respir J 2005; 25: 879-84.
101. Brenner DR, McLaughlin JR, Hung RJ. Previous lung diseases and lung cancer risk: a systematic review and meta-analysis. PLoS One 2011; 6: e17479.
102. Kiri VA, Soriano J, Visick G, Fabbri L. Recent trends in lung cancer and its association with COPD: an analysis using the uK GP Research Database. Prim Care Respir J 2010; 19: 57-61.
103. de Torres JP, Marín JM, Casanova C, Cote C, Carrizo S, Cordoba-Lanus E, et al. Lung cancer in patients with chronic obstructive pulmonary disease - incidence and predicting factors. Am J Respir Crit Care Med 2011; 184: 913-9.
104. Coultas DB, Edwards DW, Barnett B, Wludyka P. Predictors of depressive symptoms in patients with COPD and health impact. COPD 2007; 4: 23-8.
105. Hanania NA, Müllerova H, Locantore NW, Vestbo J, Watkins ML, Wouters EF, et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study investigators. Determinants of depression in the ECLIPSE chronic obstructive pulmonary disease cohort. Am J Respir Crit Care Med 2011; 183: 604-11.
106. Antonelli Incalzi R, Marra C, Giordano A, Calcagni ML, Cappa A, Basso S, Pagliari G, et al. Cognitive impairment in chronic obstructive pulmonary disease--a neuropsychological and spect study. J Neurol 2003; 250: 325-32.
107. Cote C, Zilberberg MD, Mody SH, Dordelly LJ, Celli B. Haemoglobin level and its clinical impact in a cohort of patients with COPD. Eur Respir J 2007; 29: 923-9.
108. Celli BR, Vestibo J. The EXACT-Pro: measuring exacerbations of COPD. Am J Respir Crit Care Med 2011; 183: 287-8.
109. Leidy NK, Wilcox TK, Jones PW, Roberts L, Powers JH, Sethi S; EXACT-PRO Study Group. Standardizing measurement of chronic obstructive pulmonary disease exacerbations. Reliability and validity of a patient-reported diary. Am J Respir Crit Care Med 2011; 183: 323-9.
110. Bafadhel M, McKenna S, Terry S, Mistry V, Reid C, Haldar P, et al. Acute Exacerbations of chronic obstructive pulmonary disease. Identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med 2011; 184: 662-71.
111. Tanabe N, Muro S, Hirai T, Oguma T, Terada K, Marumo S, et al. Impact of exacerbations on emphysema progression in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2011; 183: 1653-9.
112. Rizkallah J, Man SF, Sin DD. Prevalence of pulmonary embolism in acute exacerbations of COPD: a systematic review and metaanalysis. Chest 2009; 135: 786-93.
113. Aalbers R, Ayres J, Backer V, Decramer M, Lier PA, Magyar P, et al. Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial. Eur Respir J 2002; 19: 936-43.
114. Belman MJ, Botnick WC, Shin JW. Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996; 153: 967-75.
115. Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med 2000; 343: 269-80.
116. [No authors listed]. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. COMBIVENT Inhalation Aerosol Study Group. Chest 1994; 105: 1411-9.
117. van Noord JA, de Munck DR, Bantje TA, Hop WC, Akveld ML, Bommer AM. Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. Eur Respir J 2000; 15: 878-85.
118. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, et al, UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 1543-54.
119. Vogelmeier C, Hederer B, Glaab T, Schmidt H, Rutten-van Mölken P, Beeh KM, et al; POET-COPD Investigators. Tiotropium versus Salmeterol for the prevention of exacerbations of COPD. N Engl J Med 2011; 364: 1093-103.
120. Buhl R, Banerji D. Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD. Int J Chron Obstruct Pulmon Dis 2012; 7: 729-41.
121. Ulrik CS. Once-daily glycopyrronium bromide, a long-acting muscarinic antagonist, for chronic obstructive pulmonary disease: a systematic review of clinical benefit. Int J Chron Obstruct Pulmon Dis 2012; 7: 673-8.
122. Donohue JF, Fogarty C, Lotvall J, Mahler DA, Worth H, Yorgancioglu A, et al for the INHANCE study investigators. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 2010; 182: 155-62.
123. Kornmann O, Dahl R, Centanni S, Dogra A, Owen R, Lassen C, et al. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J 2011; 37: 273-9.
124. Chapman KR, Rennard SI, Dogra A, Owen R, Lassen C, Kramer B, et al. Long-term safety and efficacy of indacaterol, a long-acting β2-agonist, in subjects with COPD: a randomized, placebo-controlled study. Chest 2011; 140: 68-75.
125. Feldman G, Siler T, Prasad N, Jack D, Piggott S, Owen R, et al. Efficacy and safety of indacaterol 150 μg once-daily in COPD: a double-blind, randomised, 12-week study. BMC Pulm Med 2010; 10: 11.
126. Lowes R. FDA approves once-daily bronchodilator for COPD. Medscape Medical News. July 11, 2011.
127. Keatings VM, Jatakanon A, Worsdell YM, Barnes PJ. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med 1997; 155: 542-8.
128. Paggiaro PL, Dahle R, Bakran I, Frith L, Hollingworth K, Efthimou J. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. Lancet 1998; 351: 773-80.
129. Niewoehner DE, Erbland ML, Deupree RH, Collins D, Gross NJ, Light RW, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. N Engl J Med 1999; 340: 1941-7.
130. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al; TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775-89.
131. Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, et al; Trial of inhaled steroids and long-acting beta2 agonists study group. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361: 449-56.
132. Jones PW, Willits LR, Burge PS, Calverley PM; Inhaled Steroids in Obstructive Lung Disease in Europe study investigators. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur Respir J 2003; 21: 68-73.
133. Singh S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med 2009; 169: 219-29.
134. Calverley PM, Stockley RA, Seemungal TA, Hagan G, Willits LR, Riley JH, et al. Investigating New Standards for Prophylaxis in Reduction of Exacerbations (INSPIRE) Investigators. Reported pneumonia in patients with COPD: findings from the INSPIRE study. Chest 2011; 139: 505-12.
135. ZuWallack RL, Mahler DA, Reilly D, Church N, Emmett A, Rickard K, et al. Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest 2001; 119: 1661-70.
136. Metzger NL, Lundquist LM. A review of the advances in chronic obstructive pulmonary disease treatment. J Pharm Pract 2012; 25: 576-82.
137. Bateman ED, Rabe KF, Calverley PM, Goehring UM, Brose M, Bredenbröker D, et al. Roflumilast with long-acting β2-agonists for COPD: influence of exacerbation history. Eur Respir J 2011; 38: 553-60.
138. Rennard SI, Calverley PM, Goehring UM, Bredenbroker D, Martinez FJ. Reduction of exacerbations by the PDE4 inhibitor roflumilast-the importance of defining different subsets of patients with COPD. Respir Res 2011; 12: 8.
139. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999; 54: 581-6.
140. Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD Assessment Test. Eur Respir J 2009; 34: 648-54.
141. Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363: 1128-38.
142. [No authors listed]. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive pulmonary disease: a clinical trial. Nocturnal Oxygen-Iherapy Trial Group. Ann Intern Med 1980; 93: 391-8.
143. [No authors listed]. Long term domiciliary oxygen therapy in chronic car pulmonale complicating chronic bronchitis and emphysema Report of the Medical Research Council Working Party. Lancet 1981; 1: 681-6.
144. Celli BR, MacNee W; ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932-46.
145. Turner MO, Patel A, Ginsburg S, FitzGerald JM. Bronchodilator delivery in acute airflow obstruction. A meta-analysis. Arch Intern Med 1997; 157: 1736-44.
146. Lloberes P, Ramis L, Montserrat JM, Serra J, Campistol J, Picado C, et al. Effect of three different bronchodilators during an exacerbation of chronic obstructive pulmonary disease. Eur Respir J 1988; 1: 536-9.
147. Mahon JL, Laupacis A, Hodder RV, McKim DA, Paterson NA, Wood TE, et al. Theophylline for irreversible chronic airflow limitation: a randomized study comparing n of 1 trials to standard practice. Chest 1999; 115: 38-48.
148. Davies L, Angus RM, Calverley PM. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet 1999; 354: 456-60.
149. Aaron SD, Vandemheen KL, Hebert P, Dales R, Stiell IG, Ahuja J, et al. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. N Engl J Med 2003; 348: 2618-25.
150. Martinez FJ, Curtis JL, Albert R. Role of macrolide therapy in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2008; 3: 331-50.
151. Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JA Jr, Criner GJ, et al -for the COPD Clinical Research Network. Azithromycin for Prevention of Exacerbations of COPD. N Engl J Med 2011; 365: 689-98.
152. Anthonisen NR, Connett JE, Murray RP. Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med 2002; 166: 675-9.
153. Wilson DH, Wakefield MA, Steven ID, Rohrsheim RA, Esterman AJ, Graham NM. "Sick of Smoking": evaluation of a targeted minimal smoking cessation intervention in general practice. Med J Aust 1990; 152: 518-21.
154. Thabane M; COPD Working Group. Smoking cessation for patients with chronic obstructive pulmonary disease (COPD): an evidence-based analysis. Ont Health Technol Assess Ser 2012; 12: 1-50.
155. COPD Working Group. Pulmonary rehabilitation for patients with chronic pulmonary disease (COPD): An evidence-based analysis. Ont Health Technol Assess Ser 2012; 12: 1-75.
156. Casaburi R, Kukafka D, Cooper CB, Witek TJ Jr, Kesten S. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest 2005; 127: 809-17.
157. Landbo C, Prescott E, Lange P, Vestbo J, Almdal TP. Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160: 1856-61.
158. Jee SH, Sull JW, Park J, Lee SY, Ohrr H, Guallar E, et al. Body-mass index and mortality in Korean men and women. N Engl J Med 2006; 355: 779-87.
159. Chailleux E, Laaban JP, Veale D. Prognostic value of nutritional depletion in patients with COPD treated by long-term oxygen therapy: data from the ANTADIR observatory. Chest 2003; 123: 1460-6.
160. Anker SD, John M, Pedersen PU, Raguso C, Cicoira M, Dardai E, et al. ESPEN guidelines on enteral nutrition: cardiology and pulmonology. Clin Nutr 2006; 25: 311-8.
161. Mallampalli A. Nutritional management of the patient with chronic obstructive pulmonary disease. Nutr Clin Pract 2004; 19: 550-6.
162. Luo FM, Liu XJ, Li SQ, Wang ZL, Liu CT, Yuan YM. Circulating ghrelin in patients with chronic obstructive pulmonary disease. Nutrition 2005; 21: 793-8.
163. Nagaya N, Itoh T, Murakami S, Oya H, Uematsu M, Miyatake K, et al. Treatment of cachexia with ghrelin in patients with COPD. Chest 2005; 128: 1187-93.
164. National Emphysema Treatment Trial Research Group. Patients at high risk of death after lung volume reduction surgery. N Engl J Med 2001; 345: 1075-83.
165. Fishman A, Martinez F, Naunheim K, Piantadosi S, Wise R, Ries A, et al. National Emphysema Treatment Trial Research Group. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med 2003; 348: 2059-73.
166. Martinez FJ, Chang A. Surgical therapy for chronic obstructive pulmonary disease. Semin Respir Crit Care Med 2005; 26: 167-91.
167. Zahid I, Sharif S, Routledge T, Scarci M. Is lung volume reduction surgery effective in the treatment of advanced emphysema? Interact Cardiovasc Thorac Surg 2011; 12: 480-6.
168. Naunheim KS, Wood DE, Mohsenifar Z, Sternberg AL, Criner GJ, DeCamp MM, et al. National Emphysema Treatment Trial Research Group. Long-term follow-up of patients receiving lung-volume-reduction surgery versus medical therapy for severe emphysema by the National Emphysema Treatment Trial Research Group. Ann Thorac Surg 2006; 82: 431-43.
169. Hopkinson NS, Toma TP, Hansell DM, Goldstraw P, Moxham J, Geddes DM. Polkey MI. Effect of bronchoscopic lung volume reduction on dynamic hyperinflation and exercise in emphysema. Am J Respir Crit Care Med 2005; 171: 453-60.
170. Shah PL, Slebos DJ, Cardoso PF, Cetti E, Voelker K, Levine B, et al. Bronchoscopic lung-volume reduction with Exhale Airway Stents for Emphysema (EASE trial) randomised, sham-controlled, multicentre trial. Lancet 2011; 378: 997-1005.
171. rd. Lung transplantation: current status and challenges. Transplantation 2006; 81: 1609-15.
172. Varkey JB, Varkey AB, Varkey B. Prophylactic vaccinations in chronic obstructive pulmonary disease: current status. Curr Opin Pulm Med 2009; 15: 90-9.
173. Wongsurakiat P, Maranetra KN, Wasi C, Kositanont U, Dejsomritrutai W, Charoenratanakul S. Acute respiratory illness in patients with COPD and the effectiveness of influenza vaccination: a randomized controlled study. Chest 2004; 125: 2011-20.
174. Nichol KL, Margolis KL, Wuorenma J, Von Sternberg T. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 1994; 331: 778-84.
175. Schembri S, Morant S, Winter JH, MacDonald TM. Influenza but not pneumococcal vaccination protects against all-cause mortality in patients with COPD. Thorax 2009; 64: 567-72.
176. Jackson LA, Neuzil KM, yu O, Benson P, Barlow WE, Adams AL, et al. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med 2003; 348: 1747-55.
177. Centers for Disease Control and Prevention (CDC). Recommended adult immunization schedule, by vaccine and age-United States, 2013. Available from: http://www.cdc.gov/vaccines/schedules/hcp/imz/adult.html, accessed on February 5, 2013.
178. Pitsiou GG, Kioumis IP. Pneumococcal vaccination in adults: does it really work? Respir Med 2011; 105: 1776-83.
179. Scott LJ, Sanford M. Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed): a guide to its use in older adults. Drugs Aging 2012; 29: 847-55.
180. The Global Burden of Disease, World Health Organization. 2004. Available from: http://www.who.int/healthinfo/global_burden_disease/2004_rep, accessed on February 5, 2013.